International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects
Authors:
- 1 April 2021
- journal article
- editorial
- Published by Elsevier in Value in Health
- Vol. 24 (4) , 473-476
Abstract
No abstract availableKeywords
Funding Information
- Arnold Ventures
This publication has 11 references indexed in Scilit:
- Lessons From The Impact Of Price Regulation On The Pricing Of Anticancer Drugs In GermanyHealth Affairs, 2020
- Does external reference pricing deliver what it promises? Evidence on its impact at national levelThe European Journal of Health Economics, 2019
- The Impact Of Price Regulation On The Availability Of New Drugs In GermanyHealth Affairs, 2019
- Evolution of Average European Medicine Prices: Implications for the Methodology of External Price ReferencingPharmacoEconomics - Open, 2019
- Pharmaceutical Regulation in Central and Eastern European Countries: A Current ReviewFrontiers in Pharmacology, 2017
- Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and AustralasiaHealth Policy, 2017
- How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European CountriesApplied Health Economics and Health Policy, 2017
- The High Cost of Prescription Drugs in the United StatesJAMA, 2016
- Overview of external reference pricing systems in EuropeJournal of Market Access & Health Policy, 2015
- Impact of Cross-Reference Pricing on Pharmaceutical PricesApplied Health Economics and Health Policy, 2006